Optimer Pharmaceuticals (OPTR) vs. Sonoma Pharmaceuticals (SNOA) Head-To-Head Contrast
Optimer Pharmaceuticals (NASDAQ: OPTR) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
This table compares Optimer Pharmaceuticals and Sonoma Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for Optimer Pharmaceuticals and Sonoma Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sonoma Pharmaceuticals has a consensus target price of $10.50, indicating a potential upside of 97.37%.
Earnings and Valuation
This table compares Optimer Pharmaceuticals and Sonoma Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sonoma Pharmaceuticals||$12.82 million||1.83||$9.27 million||$1.78||2.99|
Sonoma Pharmaceuticals has higher revenue and earnings than Optimer Pharmaceuticals. Optimer Pharmaceuticals is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
9.2% of Sonoma Pharmaceuticals shares are owned by institutional investors. 13.3% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Sonoma Pharmaceuticals beats Optimer Pharmaceuticals on 6 of the 8 factors compared between the two stocks.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company’s development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer’s products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.
Receive News & Ratings for Optimer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Optimer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.